Necrosis, as Identified on Pre-Radiotherapy 18F-FDG PET/CT, is a Predictor for Complete Metabolic Response in Patients with Non-Small Cell Lung Cancer.

2021 ◽  
Author(s):  
Gülnihan Eren ◽  
Osman Kupik
Keyword(s):  
Lung Cancer ◽  
Regression Analysis ◽  
Fdg Pet ◽  
Tumor Volume ◽  
Metabolic Response ◽  
Small Cell ◽  
Small Cell Lung ◽  
Complete Metabolic Response ◽  
Pet Ct ◽  
Fdg Pet Ct

Abstract Purpose: To investigate necrosis on pre-radiotherapy (RT) 18F-FDG PET/CT (PETNECROSİS) is a predictor for complete metabolic response (CMR) in patients with non-small cell lung cancer (NSCLC).Methods: We studied patients with inoperable stage I-III NSCLC who underwent pre- and post-radiotherapy 18F-FDG PET/CT. The relationship between CMR and PETNECROSIS, SUVmax, gross tumor volume calculated with 18F-FDG PET/CT (GTVPET-CT), tumor size, histology, metabolic tumor volume (MTV), and RT dose was assessed using logistic regression analysis. To evaluate necrosis on 18F FDG PET/CT, we drew a region of interest (ROI) in the area showing visually very low/or no fluorodeoxyglucose (FDG) uptake on PET images. If the SUVmax was lower than the blood pool SUVmax and showed significantly lower attenuation [10 to 30 Hounsfield Units (HU)] from the surrounding tissue on non-intravenous contrast-enhanced low dose correlative CT, we defined it as necrotic (PETNECROSİS).Results: Fifty-three patients were included in the study. The mean age was 68.1±9.8 years. Twenty-one patients had adenocarcinoma, 32 had squamous cell carcinoma. All parameters were independent of histologic status. Multivariate logistic regression analysis showed that, SUVmax ≤11.6vs>11.6 (p=0.003, OR:7.670, 95CI%:2.013-29.231) and PETNECROSİS absence/presence were independent predictors for CMR (p=0.028, OR:6.704, 95CI%1.214-30.394).Conclusion: The necrosis on 18F FDG PET/CT and SUVmax>11.6 could be an imaging marker for the complete metabolic response after chemoradiotherapy or RT alone in patients with NSCLC.

Total metabolic tumor volume by 18F-FDG PET/CT for the prediction of outcome in patients with non-small cell lung cancer

2019 ◽  
Vol 33 (12) ◽  
pp. 937-944 ◽  
Author(s):  
Sara Pellegrino ◽  
Rosa Fonti ◽  
Emanuela Mazziotti ◽  
Luisa Piccin ◽  
Eleonora Mozzillo ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Fdg Pet ◽  
Tumor Volume ◽  
Metabolic Tumor Volume ◽  
Small Cell ◽  
Small Cell Lung ◽  
Prediction Of Outcome ◽  
Pet Ct ◽  
18F Fdg ◽  
Fdg Pet Ct

scholarly journals 18 F-FDG PET-CT during chemo-radiotherapy in patients with non-small cell lung cancer: the early metabolic response correlates with the delivered radiation dose

2012 ◽  
Vol 7 (1) ◽  
pp. 106 ◽  
Author(s):  
Mariangela Massaccesi ◽  
Maria Calcagni ◽  
Maria Spitilli ◽  
Fabrizio Cocciolillo ◽  
Francesca Pelligrò ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Radiation Dose ◽  
Small Cell Lung Cancer ◽  
Fdg Pet ◽  
Metabolic Response ◽  
Small Cell ◽  
Small Cell Lung ◽  
Pet Ct ◽  
Fdg Pet Ct ◽  
Early Metabolic Response

Predictive Value of Interim 18F-FDG-PET in Patients with Non-Small Cell Lung Cancer Treated with Definitive Radiation Therapy

2020 ◽  
Author(s):  
Nalee Kim ◽  
Jin Sung Kim ◽  
Chang Geol Lee
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Predictive Value ◽  
Fdg Pet ◽  
Metabolic Response ◽  
Small Cell ◽  
Small Cell Lung ◽  
Pet Ct ◽  
Fdg Pet Ct

Abstract Background We evaluated that early metabolic response determined by 18 F-fluorodeoxyglucose positron emission tomography/computed tomography (FDG-PET/CT) during radiotherapy (RT), predicts outcomes in non-small cell lung cancer. Methods Twenty-eight patients evaluated using pretreatment 18 F-FDG-PET/CT (PET pre ) and interim 18 F-FDG-PET/CT (PET interim ) after 11 fractions of RT were retrospectively reviewed. Maximum standardized uptake value (SUV max ) was calculated for primary lesion. Predictive value of gross tumor volume (△GTV) and SUV max (△SUV max ) changes was evaluated for locoregional control (LRC), distant failure (DF), and overall survival (OS). Metabolic responders were patients with △SUV max >40%. Results Metabolic responders showed better trends in 1-year LRC (90.9%) than non-responders (47.1%) (p=0.086). Patients with large GTV pre (≥120 cc) demonstrated poor LRC (hazard ratio 4.14, p = 0.022), while metabolic non-responders with small GTV pre (<120 cc) and metabolic responders with large GTV pre both had 1-year LRC rates of 75.0%. Reduction of 25% in GTV was not associated with LRC; however, metabolic responders without a GTV response showed better 1-year LRC (83.3%) than metabolic non-responders with a reduction in GTV (42.9%). Metabolic responders showed lower 1-year DF (16.7%) than non-responders (50.0%) (p=0.025). An ΔSUV max threshold of 40% yielded accuracy of 64% for predicting LRC, 75% for DF, and 54% for OS. However, ΔGTV > 25% demonstrated inferior diagnostic values than metabolic response. Conclusions Changes in tumor metabolism diagnosed using PET interim during RT better predicted treatment responses, recurrences, and prognosis than other factors historically used.

Impact of FDG PET/CT on Delineation of the Gross Tumor Volume for Radiation Planning in Non–Small-Cell Lung Cancer

2010 ◽  
Vol 35 (4) ◽  
pp. 237-243 ◽  
Author(s):  
Daniel E. Spratt ◽  
Roberto Diaz ◽  
James McElmurray ◽  
Ildiko Csiki ◽  
Dennis Duggan ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Fdg Pet ◽  
Gross Tumor Volume ◽  
Tumor Volume ◽  
Small Cell ◽  
Small Cell Lung ◽  
Pet Ct ◽  
Fdg Pet Ct ◽  
Radiation Planning

18F-FDG PET/CT Mean SUV and Metabolic Tumor Volume for Mean Survival Time in Non–Small Cell Lung Cancer

2015 ◽  
Vol 40 (6) ◽  
pp. 459-463 ◽  
Author(s):  
Ercan Kurtipek ◽  
Mustafa Çayc ◽  
Nuri Düzgün ◽  
Hdr Esme ◽  
Yüksel Terzi ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Fdg Pet ◽  
Tumor Volume ◽  
Metabolic Tumor Volume ◽  
Small Cell ◽  
Small Cell Lung ◽  
Mean Survival Time ◽  
Pet Ct ◽  
18F Fdg ◽  
Fdg Pet Ct

scholarly journals Baseline metabolic tumor volume as a strong predictive and prognostic biomarker in patients with non-small cell lung cancer treated with PD1 inhibitors: a prospective study

2020 ◽  
Vol 8 (2) ◽  
pp. e000645
Author(s):  
David Chardin ◽  
Marie Paquet ◽  
Renaud Schiappa ◽  
Jacques Darcourt ◽  
Caroline Bailleux ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Fdg Pet ◽  
Tumor Volume ◽  
Metabolic Tumor Volume ◽  
Small Cell ◽  
Ct Scans ◽  
Small Cell Lung ◽  
Pet Ct ◽  
Fdg Pet Ct

BackgroundReliable predictive and prognostic markers are still lacking for patients treated with programmed death receptor 1 (PD1) inhibitors for non-small cell lung cancer (NSCLC). The purpose of this study was to investigate the prognostic and predictive values of different baseline metabolic parameters, including metabolic tumor volume (MTV), from 18F-fluorodeoxyglucose positron emission tomography–computed tomography (18F-FDG PET/CT) scans in patients with NSCLC treated with PD1 inhibitors.MethodsMaximum and peak standardized uptake values, MTV and total lesion glycolysis (TLG), as well as clinical and biological parameters, were recorded in 75 prospectively included patients with NSCLC treated with PD1 inhibitors. Associations between these parameters and overall survival (OS) were evaluated as well as their accuracy to predict early treatment discontinuation (ETD).ResultsA high MTV and a high TLG were significantly associated with a lower OS (p<0.001). The median OS in patients with MTV above the median (36.5 cm3) was 10.5 months (95% CI: 6.2 to upper limit: unreached), while the median OS in patients with MTV below the median was not reached. Patients with no prior chemotherapy had a poorer OS than patients who had received prior systemic treatment (p=0.04). MTV and TLG could reliably predict ETD (area under the receiver operating characteristic curve=0.76, 95% CI: 0.65 to 0.87 and 0.72, 95% CI: 0.62 to 0.84, respectively).ConclusionMTV is a strong prognostic and predictive factor in patients with NSCLC treated with PD1 inhibitors and can be easily determined from routine 18F-FDG PET/CT scans. MTV, could help to personalize immunotherapy and be used to stratify patients in future clinical studies.

Sign in / Sign up

Export Citation Format

Share Document